Appendix 4D - Half-year Financial Report - 31 December 2025
Filed with ASX · · 28 pages · English
Dividends There were no dividends paid, recommended or declared during the current financial period. Comments The loss for the consolidated entity after providing for income tax amounted to $5,537,336 (31 December 2024: $7,279,761). The net assets of the consolidated entity were $8,285,247 at 31 December 2025 (30 June 2025: net assets of $2,820,571). 7. Dividend reinvestment plans Not applicable.
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- Appendix 4C & Quarterly Update
- Neurizon secures $6million R&D Tax Incentive Rebate
- Neurizon Completes Entitlement Offer
- Global Trademark Protection Secured Across Key Markets
- Regulatory and Development Update
Later from Neurizon Therapeutics
- Neurizon Initiates Dosing in HEALEY ALS Platform Trial
- Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
- Neurizon announces leadership transition
- NUZ-001 Data Shows Multi-Pathway Protein Clearance
- Placement of Entitlement Offer Shortfall
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics